| Source: |
| Type: |
| Glycolysis is a metabolic pathway that converts glucose into pyruvate, producing a small amount of ATP (energy) in the process. It is a fundamental process for cellular energy production and occurs in the cytoplasm of cells. In normal cells, glycolysis is tightly regulated and is followed by aerobic respiration in the presence of oxygen, which allows for the efficient production of ATP. In cancer cells, however, glycolysis is often upregulated, even in the presence of oxygen. This phenomenon is known as the Warburg Mutations in oncogenes (like MYC) and tumor suppressor genes (like TP53) can alter metabolic pathways, promoting glycolysis and other anabolic processes that support cell growth.effect. Acidosis: The increased production of lactate from glycolysis can lead to an acidic microenvironment, which may promote tumor invasion and suppress immune responses. Glycolysis is a hallmark of malignancy transformation in solid tumor, and LDH is the key enzyme involved in glycolysis. Pathways: -GLUTs, HK2, PFK, PK, PKM2, LDH, LDHA, PI3K/AKT/mTOR, AMPK, HIF-1a, c-MYC, p53, SIRT6, HSP90α, GAPDH, HBT, PPP, Lactate Metabolism, ALDO Natural products targeting glycolytic signaling pathways https://pmc.ncbi.nlm.nih.gov/articles/PMC9631946/ Alkaloids: -Berberine, Worenine, Sinomenine, NK007, Tetrandrine, N-methylhermeanthidine chloride, Dauricine, Oxymatrine, Matrine, Cryptolepine Flavonoids: -Oroxyline A, Apigenin, Kaempferol, Quercetin, Wogonin, Baicalein, Chrysin, Genistein, Cardamonin, Phloretin, Morusin, Bavachinin, 4-O-methylalpinumisofavone, Glabridin, Icaritin, LicA, Naringin, IVT, Proanthocyanidin B2, Scutellarin, Hesperidin, Silibinin, Catechin, EGCG, EGC, Xanthohumol. Non-flavonoid phenolic compounds: Curcumin, Resveratrol, Gossypol, Tannic acid. Terpenoids: -Cantharidin, Dihydroartemisinin, Oleanolic acid, Jolkinolide B, Cynaropicrin, Ursolic Acid, Triptolie, Oridonin, Micheliolide, Betulinic Acid, Beta-escin, Limonin, Bruceine D, Prosapogenin A (PSA), Oleuropein, Dioscin. Quinones: -Thymoquinone, Lapachoi, Tan IIA, Emodine, Rhein, Shikonin, Hypericin Others: -Perillyl alcohol, HCA, Melatonin, Sulforaphane, Vitamin D3, Mycoepoxydiene, Methyl jasmonate, CK, Phsyciosporin, Gliotoxin, Graviola, Ginsenoside, Beta-Carotene. |
| 2409- | PTS, | Pterostilbene Induces Pyroptosis in Breast Cancer Cells through Pyruvate Kinase 2/Caspase-8/Gasdermin C Signaling Pathway |
| - | in-vitro, | BC, | EMT6 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Nor, | HC11 |
| 3374- | QC, | Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis |
| - | Review, | Oral, | NA | - | Review, | AD, | NA |
| 1201- | QC, | Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1 |
| - | in-vivo, | BC, | NA |
| 910- | QC, | The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism |
| - | Review, | Var, | NA |
| 2340- | QC, | Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
| - | in-vitro, | OS, | NA |
| 2300- | QC, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2344- | QC, | Quercetin: A natural solution with the potential to combat liver fibrosis |
| - | Review, | Nor, | NA |
| 2342- | QC, | Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway |
| - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vivo, | NA, | NA |
| 2341- | QC, | Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 993- | RES, | Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells |
| - | in-vitro, | CRC, | Caco-2 | - | in-vivo, | Nor, | HCEC 1CT |
| 2331- | RES, | Resveratrol improves follicular development of PCOS rats via regulating glycolysis pathway and targeting SIRT1 |
| - | in-vivo, | Nor, | NA |
| 2332- | RES, | Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism |
| - | Review, | Var, | NA |
| 2333- | RES, | Resveratrol regulates insulin resistance to improve the glycolytic pathway by activating SIRT2 in PCOS granulosa cells |
| - | in-vitro, | Nor, | NA |
| 2439- | RES, | By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vitro, | Nor, | L02 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | HUH7 |
| 2441- | RES, | Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions |
| - | Review, | Var, | NA |
| 2440- | RES, | Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway |
| - | in-vitro, | Lung, | H460 | - | in-vivo, | Lung, | NA | - | in-vitro, | Lung, | H1650 | - | in-vitro, | Lung, | HCC827 |
| 3055- | RES, | Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets |
| - | Review, | Var, | NA |
| 3026- | RosA, | Modulatory Effect of Rosmarinic Acid on H2O2-Induced Adaptive Glycolytic Response in Dermal Fibroblasts |
| - | in-vitro, | Nor, | NA |
| 3036- | RosA, | Anti-Warburg effect of rosmarinic acid via miR-155 in colorectal carcinoma cells |
| - | in-vitro, | CRC, | HCT8 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LS174T |
| 3935- | RT, | Sodium rutin ameliorates Alzheimer's disease-like pathology by enhancing microglial amyloid-β clearance |
| - | in-vivo, | AD, | NA |
| 4906- | Sal, | A Concise Review of Prodigious Salinomycin and Its Derivatives Effective in Treatment of Breast Cancer: (2012–2022) |
| - | Review, | BC, | NA |
| 3195- | SFN, | AKT1/HK2 Axis-mediated Glucose Metabolism: A Novel Therapeutic Target of Sulforaphane in Bladder Cancer |
| - | in-vitro, | Bladder, | UMUC3 |
| 2406- | SFN, | Sulforaphane and Its Protective Role in Prostate Cancer: A Mechanistic Approach |
| - | Review, | Pca, | NA |
| 2405- | SFN, | Sulforaphane Targets the TBX15/KIF2C Pathway to Repress Glycolysis and Cell Proliferation in Gastric Carcinoma Cells |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | BGC-823 |
| 2404- | SFN, | Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vivo, | NA, | NA |
| 2403- | SFN, | Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 | - | in-vivo, | NA, | NA |
| 2446- | SFN, | CAP, | The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor |
| - | in-vitro, | Pca, | LNCaP |
| 2448- | SFN, | Sulforaphane and bladder cancer: a potential novel antitumor compound |
| - | Review, | Bladder, | NA |
| 1452- | SFN, | Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells |
| - | in-vitro, | GC, | AGS |
| 1484- | SFN, | Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 1481- | SFN, | docx, | Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 1734- | SFN, | Sulforaphane Inhibits Nonmuscle Invasive Bladder Cancer Cells Proliferation through Suppression of HIF-1α-Mediated Glycolysis in Hypoxia |
| - | in-vitro, | Bladder, | RT112 |
| 2410- | SIL, | Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
| 1140- | SIL, | Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth |
| - | in-vitro, | PC, | AsPC-1 | - | in-vivo, | PC, | NA | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 1001- | SIL, | Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism |
| - | in-vitro, | NPC, | NA |
| 2418- | SK, | Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2 |
| - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 |
| 2419- | SK, | Regulation of glycolysis and the Warburg effect in wound healing |
| - | in-vivo, | Nor, | NA |
| 2415- | SK, | Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways |
| - | in-vivo, | Arthritis, | NA |
| 2359- | SK, | Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery |
| - | in-vivo, | Liver, | NA |
| 2356- | SK, | ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment |
| - | in-vitro, | Ovarian, | CaOV3 | - | in-vitro, | Ovarian, | OV90 | - | in-vivo, | NA, | NA |
| 2357- | SK, | GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism |
| - | Study, | HCC, | NA | - | in-vivo, | NA, | NA |
| 2370- | SK, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 2362- | SK, | RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | GBM, | NA | - | in-vitro, | GBM, | U251 |
| 2200- | SK, | Shikonin inhibits the growth of anaplastic thyroid carcinoma cells by promoting ferroptosis and inhibiting glycolysis |
| - | in-vitro, | Thyroid, | CAL-62 | - | in-vitro, | Thyroid, | 8505C |
| 2196- | SK, | Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species |
| - | Review, | Var, | NA |
| 2192- | SK, | Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation |
| - | in-vitro, | ESCC, | KYSE-510 | - | in-vitro, | ESCC, | Eca109 | - | in-vivo, | NA, | NA |
| 2187- | SK, | VitK3, | Shikonin, vitamin K3 and vitamin K5 inhibit multiple glycolytic enzymes in MCF-7 cells |
| - | in-vitro, | BC, | MCF7 |
| 2186- | SK, | Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HCCLM3 |
| 2185- | SK, | Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis |
| - | in-vitro, | Lung, | LLC1 | - | in-vitro, | Melanoma, | B16-BL6 | - | in-vivo, | NA, | NA |
| 2182- | SK, | Cisplatin, | Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:129 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid